Reducing tau ameliorates behavioural and transcriptional deficits in a novel model of Alzheimer’s disease

Eleanor K. Pickett, Abigail G. Herrmann, Jamie McQueen, Kimberly M. Abt, Owen Dando, Jane Tulloch, Pooja Jain, Sophie Dunnett, Sadaf Sohrabi, Maria P. Fjeldstad, Will Calkin, Leo Murison, Rosemary J. Jackson, Makis Tzioras, Anna J. Stevenson, Marie d’Orange, Monique Hooley, C. T. M. Davies, Iris Oren, Jamie Rose, Chris-Anne McKenzie, Elizabeth Allison, Colin Smith, Oliver Hardt, Christopher M. Henstridge, Giles E. Hardingham, Tara L. Spires‐JonesBiorxiv 2018 · DOI

TL;DR

This study introduces a novel mouse model for Alzheimer's disease (AD) that combines amyloid-beta (Aβ) and tau pathology. They found that both proteins work together to cause behavioral deficits and alter gene expression, particularly affecting synaptic function. Crucially, reducing tau levels, especially at synapses, reversed these deficits, suggesting a promising therapeutic avenue for AD.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles composed of tau protein. While both are implicated in disease, the precise mechanisms by which they interact and contribute to cognitive decline and neuronal dysfunction remain a significant knowledge gap. Current treatments are largely ineffective, highlighting the urgent need to understand these complex interactions to develop better therapies. Specifically, this paper aims to elucidate how Aβ and tau cooperate to cause disease phenotypes, focusing on their combined impact on molecular, cellular, and behavioral aspects of AD.

Methods

The researchers developed a novel mouse model, termed MAPT-AD, by combining a mouse line lacking endogenous tau (MAPTnull) with a transgene expressing human amyloid precursor protein (APP) and presenilin 1 (PS1) to induce Aβ pathology, and another transgene for regulatable human wild-type tau. This model allows for controlled expression of human tau, which can be suppressed by doxycycline.

Key techniques employed include:

  • Behavioral testing: Open field tests were used to assess hyperactivity and anxiety-like behaviors in the mice.
  • Histopathology: Staining with Thioflavin S and antibodies against Aβ and tau (phosphorylated and misfolded forms) was used to quantify plaque burden and tau pathology.
  • Array Tomography: This high-resolution imaging technique was used to examine the localization of Aβ and tau at synaptic terminals in both mouse models and human post-mortem brain tissue.
  • RNA sequencing (RNA-seq): This was performed on brain tissue to identify global transcriptional changes and assess how these changes are affected by tau suppression.
  • Quantitative Reverse Transcription PCR (qRT-PCR): Used to validate RNA-seq findings for specific genes.

Datasets

The study utilized:

  • Mouse models:
    • MAPTnull mice (lacking endogenous tau)
    • APP/PS1 mice (expressing human familial AD mutant APP and PS1)
    • MAPTnull mice expressing human tau transgene (rTg21221)
    • MAPT-AD mice (combining APP/PS1 and regulatable human tau)
  • Human post-mortem brain tissue: Samples from individuals with Alzheimer's disease and age-matched controls.
  • RNA-seq data: Generated from frontal cortex of MAPT-AD mice and control genotypes.

Key Insights and Ideas

  • Synergistic Action of Aβ and Tau: The study strongly supports the idea that Aβ and tau don't act in isolation but rather cooperate to drive AD pathology. Their combined presence leads to more severe deficits than either protein alone.
  • Synaptic Tau is Crucial: The accumulation of pathological tau in synapses, observed in both the mouse model and human AD brains, is highlighted as a key player. This suggests that targeting tau at the synapse might be particularly effective.
  • Reversibility of Deficits: A major breakthrough is the finding that reducing tau levels, even after behavioral and transcriptional deficits have emerged, can reverse these problems. This implies that AD might not be a purely progressive, irreversible disease at all stages.
  • Transcriptional Rewiring: The researchers identified significant changes in gene expression, with a notable downregulation of genes involved in synaptic function and an upregulation of inflammatory genes. This provides a molecular basis for the observed behavioral and synaptic deficits.

Key Results

  • MAPT-AD mice developed an age-related hyperactivity phenotype and significant downregulation of genes involved in synaptic function.
  • Both Aβ and tau were found to accumulate in pre- and postsynaptic terminals in MAPT-AD mice and human AD brains.
  • Reducing tau expression with doxycycline in MAPT-AD mice ameliorated hyperactivity, reduced synaptic tau levels, and reversed many of the transcriptional changes.
  • RNA-seq revealed that upregulated genes in MAPT-AD mice were largely driven by Aβ or tau independently, while downregulated genes showed an additive effect of both proteins.
  • Synapse density near plaques was reduced in both APP/PS1 and MAPT-AD mice, but this was not rescued by tau suppression.

Limitations and Future Work

  • Model Limitations: While the MAPT-AD model is novel and informative, it's important to acknowledge that it's a model and may not perfectly recapitulate all aspects of human AD. The study notes that tau pathology (tangles) did not accumulate in the MAPT-AD mice, which is a key feature of human AD.
  • Tau Localization: While tau was found in synapses, its precise role in different synaptic compartments (pre- vs. post-synaptic) and its interaction with Aβ within the same synapse require further investigation. The study found very rare co-localization of Aβ and tau within individual synapses.
  • Therapeutic Translation: The findings in mice are promising, but further research is needed to translate these results into effective human therapies. The study suggests that lowering pathological tau, particularly at synapses, may be a viable therapeutic strategy.
  • Non-neuronal Cells: The RNA-seq data also implicated non-neuronal cells (glia) in the interplay between Aβ and tau, suggesting that targeting neuroinflammation could also be a beneficial approach.

Summary updated

Abstract

Summary One of the key knowledge gaps blocking development of effective therapeutics for Alzheimer’s disease (AD) is the lack of understanding of how amyloid beta (Aβ) and tau cooperate in causing disease phenotypes. Within a mouse tau deficient background, we probed the molecular, cellular and behavioural disruption triggered by wild-type human tau’s influence on human Aβ-induced pathology. We find that Aβ and tau work cooperatively to cause a hyperactivity phenotype and to cause downregulation of gene transcription including many involved in synaptic function. In both our mouse model and in human post-mortem tissue, we observe accumulation of pathological tau in synapses, supporting the potential importance of synaptic tau. Importantly, tau depletion in the mice, initiated after behavioural deficits emerge, was found to correct behavioural deficits, reduce synaptic tau levels, and substantially reverse transcriptional perturbations, suggesting that lowering tau levels, particularly at the synapse, may be beneficial in AD. Highlights - Expression of human familial Alzheimer’s associated mutant amyloid precursor protein and presenillin 1 with wild-type human tau in the absence of endogenous tau in a novel MAPT-AD mouse model results in behavioural deficits and downregulation of genes involved in synaptic function. - Tau is present in pre and postsynaptic terminals in MAPT-AD mice and human AD brain. In mice, lowering synaptic tau levels was associated with improved cognition and recovered gene expression. - These data suggest that Aβ and tau act cooperatively in impairing synaptic function and that lowering tau at synapses could be a beneficial therapeutic approach in AD.
BibTeX
@misc{pickett2018reducing,
  author = {Eleanor K. Pickett and Abigail G. Herrmann and Jamie McQueen and Kimberly M. Abt and Owen Dando and Jane Tulloch and Pooja Jain and Sophie Dunnett and Sadaf Sohrabi and Maria P. Fjeldstad and Will Calkin and Leo Murison and Rosemary J. Jackson and Makis Tzioras and Anna J. Stevenson and Marie d’Orange and Monique Hooley and C. T. M. Davies and Iris Oren and Jamie Rose and Chris-Anne McKenzie and Elizabeth Allison and Colin Smith and Oliver Hardt and Christopher M. Henstridge and Giles E. Hardingham and Tara L. Spires‐Jones},
  title = {{Reducing tau ameliorates behavioural and transcriptional deficits in a novel model of Alzheimer’s disease}},
  year = {2018},
  doi = {10.1101/393405},
  howpublished = {Biorxiv},
}
Figure